803 related articles for article (PubMed ID: 28502591)
21. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
22. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease.
Shinzaki S; Iijima H; Nakagawa T; Egawa S; Nakajima S; Ishii S; Irie T; Kakiuchi Y; Nishida T; Yasumaru M; Kanto T; Tsujii M; Tsuji S; Mizushima T; Yoshihara H; Kondo A; Miyoshi E; Hayashi N
Am J Gastroenterol; 2008 May; 103(5):1173-81. PubMed ID: 18177457
[TBL] [Abstract][Full Text] [Related]
23. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China.
Jiang L; Xia B; Li J; Ye M; Yan W; Deng C; Ding Y; Luo H; Hou W; Zhao Q; Liu N; Ren H; Hou X; Xu H
Inflamm Bowel Dis; 2006 Mar; 12(3):212-7. PubMed ID: 16534423
[TBL] [Abstract][Full Text] [Related]
24. Disequilibrium in the CD8
Dai S; Gu H; Lin Q; Xing T; Chen M; Zhong T; Wu G; Feng Y; Liu H; Gao Y; Jian H; Zhang M; Mo H; Zhu H; Chen D; Xu J; Zou Y; Chi H; Zhu Y
Dig Dis Sci; 2017 Mar; 62(3):639-651. PubMed ID: 28035546
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
[TBL] [Abstract][Full Text] [Related]
27. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells.
Baumgart DC; Metzke D; Schmitz J; Scheffold A; Sturm A; Wiedenmann B; Dignass AU
Gut; 2005 Feb; 54(2):228-36. PubMed ID: 15647187
[TBL] [Abstract][Full Text] [Related]
28. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity.
Abad E; Tural C; Mirapeix E; Cuxart A
J Autoimmun; 1997 Apr; 10(2):175-80. PubMed ID: 9185879
[TBL] [Abstract][Full Text] [Related]
29. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis.
Tanaka M; Riddell RH; Saito H; Soma Y; Hidaka H; Kudo H
Scand J Gastroenterol; 1999 Jan; 34(1):55-67. PubMed ID: 10048734
[TBL] [Abstract][Full Text] [Related]
30. Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.
Saadah OI; Al-Harthi SE; Al-Mughales JA; Bin-Taleb YY; Baeshen RS
Int J Clin Exp Pathol; 2015; 8(12):16000-6. PubMed ID: 26884875
[TBL] [Abstract][Full Text] [Related]
31. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease.
Hisamatsu T; Okamoto S; Hashimoto M; Muramatsu T; Andou A; Uo M; Kitazume MT; Matsuoka K; Yajima T; Inoue N; Kanai T; Ogata H; Iwao Y; Yamakado M; Sakai R; Ono N; Ando T; Suzuki M; Hibi T
PLoS One; 2012; 7(1):e31131. PubMed ID: 22303484
[TBL] [Abstract][Full Text] [Related]
32. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).
Henriksen M; Jahnsen J; Lygren I; Sauar J; Schulz T; Stray N; Vatn MH; Moum B;
Scand J Gastroenterol; 2006 Sep; 41(9):1037-43. PubMed ID: 16938716
[TBL] [Abstract][Full Text] [Related]
33. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
Solem CA; Loftus EV; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
Inflamm Bowel Dis; 2005 Aug; 11(8):707-12. PubMed ID: 16043984
[TBL] [Abstract][Full Text] [Related]
34. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005.
Herrinton LJ; Liu L; Fireman B; Lewis JD; Allison JE; Flowers N; Hutfless S; Velayos FS; Abramson O; Altschuler A; Perry GS
Gastroenterology; 2009 Aug; 137(2):502-11. PubMed ID: 19445944
[TBL] [Abstract][Full Text] [Related]
35. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
36. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
Mokrowiecka A; Gasiorowska A; Małecka-Panas E
Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
[TBL] [Abstract][Full Text] [Related]
37. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
[TBL] [Abstract][Full Text] [Related]
38. [Expression of elafin in peripheral blood in inflammatory bowel disease patients and its clinical significance].
Zhang W; Teng GG; Tian Y; Wang HH
Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(14):1120-3. PubMed ID: 27095781
[TBL] [Abstract][Full Text] [Related]
39. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
Horton N; Wu X; Philpott J; Garber A; Achkar JP; Brzezinski A; Lashner BA; Shen B
Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393
[TBL] [Abstract][Full Text] [Related]
40. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission.
Herrlinger KR; Noftz MK; Dalhoff K; Ludwig D; Stange EF; Fellermann K
Am J Gastroenterol; 2002 Feb; 97(2):377-81. PubMed ID: 11866276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
